In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
September 27th, 2005 | 28 | Yes |
Popular Name: Amsacrine Amsacrine
Find On: PubMed — Wikipedia — Google
CAS Numbers: 51264-14-3 , 54301-15-4
4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide; 51264-14-3; Amsacrine; C01553; mAMSA
51264-14-3; Amsacrine (USAN/INN); Amsidyl (TN); D02321
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 4.91 | 6.33 | -44.52 | 2 | 6 | 0 | 84 | 393.468 | 5 | ↓ |
Hi High (pH 8-9.5) | 4.91 | 5.83 | -16.62 | 2 | 6 | 0 | 80 | 393.468 | 5 | ↓ |
Hi High (pH 8-9.5) | 4.91 | 5.94 | -47.33 | 1 | 6 | -1 | 82 | 392.46 | 5 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
ALOGPS_SOLUBILITY | 3.17e-03 g/l | DrugBank-approved |
UniProt Database Links | ALDO1_ARATH; ALDO2_ARATH; TOP2A_HUMAN | ChEBI |
Patent Database Links | EP1728863; EP1772452; EP1938798; EP1977765; US2004132722; US2005101646; US2005124621; US2005130980; US2005159420; US2005192310; US2005197339; US2005222153; US2006014745; US2006014755; US2006030555; US2006035945; US2006040958; US2006041131; US2006058304; U | ChEBI |
Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
KCNH2-2-E | HERG (cluster #2 Of 5), Eukaryotic | Eukaryotes | 210 | 0.33 | Binding ≤ 10μM |
S22A1-1-E | Solute Carrier Family 22 Member 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 5000 | 0.27 | Binding ≤ 10μM |
TOP2A-1-E | DNA Topoisomerase II Alpha (cluster #1 Of 2), Eukaryotic | Eukaryotes | 9940 | 0.25 | Binding ≤ 10μM |
TOP2B-1-E | DNA Topoisomerase II Beta (cluster #1 Of 2), Eukaryotic | Eukaryotes | 720 | 0.31 | Binding ≤ 10μM |
TOP1-1-E | DNA Topoisomerase I (cluster #1 Of 1), Eukaryotic | Eukaryotes | 20 | 0.38 | Functional ≤ 10μM |
TOP2A-1-E | DNA Topoisomerase II Alpha (cluster #1 Of 1), Eukaryotic | Eukaryotes | 20 | 0.38 | Functional ≤ 10μM |
TOP2B-1-E | DNA Topoisomerase II Beta (cluster #1 Of 1), Eukaryotic | Eukaryotes | 20 | 0.38 | Functional ≤ 10μM |
ADO-1-E | Aldehyde Oxidase (cluster #1 Of 3), Eukaryotic | Eukaryotes | 6400 | 0.26 | ADME/T ≤ 10μM |
CP2D6-2-E | Cytochrome P450 2D6 (cluster #2 Of 3), Eukaryotic | Eukaryotes | 7500 | 0.26 | ADME/T ≤ 10μM |
Z103205-3-O | A431 (cluster #3 Of 4), Other | Other | 5890 | 0.26 | Functional ≤ 10μM |
Z50425-3-O | Plasmodium Falciparum (cluster #3 Of 22), Other | Other | 600 | 0.31 | Functional ≤ 10μM |
Z50460-4-O | Leishmania Major (cluster #4 Of 4), Other | Other | 1500 | 0.29 | Functional ≤ 10μM |
Z80064-8-O | CCRF-CEM (T-cell Leukemia) (cluster #8 Of 9), Other | Other | 139 | 0.34 | Functional ≤ 10μM |
Z80084-1-O | CEM-VLB (Vinblastine-resistant T-cell Leukemia Cells) (cluster #1 Of 2), Other | Other | 520 | 0.31 | Functional ≤ 10μM |
Z80085-1-O | CEM-VM1 (Etoposide-resistant T-cell Leukemia Cells) (cluster #1 Of 2), Other | Other | 1910 | 0.29 | Functional ≤ 10μM |
Z80089-1-O | CHO-AA8 (cluster #1 Of 2), Other | Other | 1 | 0.45 | Functional ≤ 10μM |
Z80115-1-O | DC3F (cluster #1 Of 1), Other | Other | 4 | 0.42 | Functional ≤ 10μM |
Z80117-2-O | DC3F/AD-II (cluster #2 Of 2), Other | Other | 47 | 0.37 | Functional ≤ 10μM |
Z80152-1-O | HCT-8 (Ileocecal Adenocarcinoma) (cluster #1 Of 2), Other | Other | 120 | 0.35 | Functional ≤ 10μM |
Z80156-1-O | HL-60 (Promyeloblast Leukemia Cells) (cluster #1 Of 12), Other | Other | 6 | 0.41 | Functional ≤ 10μM |
Z80166-1-O | HT-29 (Colon Adenocarcinoma Cells) (cluster #1 Of 12), Other | Other | 559 | 0.31 | Functional ≤ 10μM |
Z80186-6-O | K562 (Erythroleukemia Cells) (cluster #6 Of 11), Other | Other | 23 | 0.38 | Functional ≤ 10μM |
Z80193-2-O | L1210 (Lymphocytic Leukemia Cells) (cluster #2 Of 12), Other | Other | 50 | 0.37 | Functional ≤ 10μM |
Z80224-5-O | MCF7 (Breast Carcinoma Cells) (cluster #5 Of 14), Other | Other | 75 | 0.36 | Functional ≤ 10μM |
Z80227-2-O | MCF7-ADR (Breast Carcinoma Cells) (cluster #2 Of 2), Other | Other | 1165 | 0.30 | Functional ≤ 10μM |
Z80244-7-O | MDA-MB-468 (Breast Adenocarcinoma) (cluster #7 Of 7), Other | Other | 490 | 0.32 | Functional ≤ 10μM |
Z80322-1-O | NCI-H358 (Lung Carcinama Cells) (cluster #1 Of 2), Other | Other | 150 | 0.34 | Functional ≤ 10μM |
Z80362-1-O | P388 (Lymphoma Cells) (cluster #1 Of 8), Other | Other | 890 | 0.30 | Functional ≤ 10μM |
Z80475-3-O | SK-BR-3 (Breast Adenocarcinoma) (cluster #3 Of 3), Other | Other | 60 | 0.36 | Functional ≤ 10μM |
Z80601-1-O | XRS6 (cluster #1 Of 1), Other | Other | 240 | 0.33 | Functional ≤ 10μM |
Z80608-4-O | ZR-75-1 (Breast Carcinoma Cells) (cluster #4 Of 4), Other | Other | 180 | 0.34 | Functional ≤ 10μM |
Z80612-1-O | 2008 (Ovarian Carcinoma Cells) (cluster #1 Of 2), Other | Other | 4310 | 0.27 | Functional ≤ 10μM |
Z80682-1-O | A549 (Lung Carcinoma Cells) (cluster #1 Of 11), Other | Other | 3520 | 0.27 | Functional ≤ 10μM |
Z80712-7-O | T47D (Breast Carcinoma Cells) (cluster #7 Of 7), Other | Other | 220 | 0.33 | Functional ≤ 10μM |
Z80819-1-O | J774.2 (cluster #1 Of 1), Other | Other | 1485 | 0.29 | Functional ≤ 10μM |
Z80846-2-O | F460pv8/eto Cell Line (cluster #2 Of 2), Other | Other | 40 | 0.37 | Functional ≤ 10μM |
Z80889-2-O | NCI-H322M (Non-small Cell Lung Carcinoma Cells) (cluster #2 Of 3), Other | Other | 210 | 0.33 | Functional ≤ 10μM |
Z80928-5-O | HCT-116 (Colon Carcinoma Cells) (cluster #5 Of 9), Other | Other | 700 | 0.31 | Functional ≤ 10μM |
Z81024-8-O | NCI-H460 (Non-small Cell Lung Carcinoma) (cluster #8 Of 8), Other | Other | 60 | 0.36 | Functional ≤ 10μM |
Z81034-6-O | A2780 (Ovarian Carcinoma Cells) (cluster #6 Of 10), Other | Other | 100 | 0.35 | Functional ≤ 10μM |
Z81072-6-O | Jurkat (Acute Leukemic T-cells) (cluster #6 Of 10), Other | Other | 80 | 0.35 | Functional ≤ 10μM |
Z81160-1-O | Lewis Lung Carcinoma Cell Line (cluster #1 Of 1), Other | Other | 12 | 0.40 | Functional ≤ 10μM |
Z81164-1-O | LL Cell Line (cluster #1 Of 2), Other | Other | 12 | 0.40 | Functional ≤ 10μM |
Z81167-1-O | LLTC Cell Line (cluster #1 Of 1), Other | Other | 12 | 0.40 | Functional ≤ 10μM |
Z81244-1-O | J774 (Macrophage Cells) (cluster #1 Of 1), Other | Other | 901 | 0.30 | Functional ≤ 10μM |
Z81247-2-O | HeLa (Cervical Adenocarcinoma Cells) (cluster #2 Of 9), Other | Other | 9500 | 0.25 | Functional ≤ 10μM |
Z81252-10-O | MDA-MB-231 (Breast Adenocarcinoma Cells) (cluster #10 Of 11), Other | Other | 140 | 0.34 | Functional ≤ 10μM |
Z81280-1-O | NCI-H226 (Non-small Cell Lung Carcinoma Cells) (cluster #1 Of 3), Other | Other | 1010 | 0.30 | Functional ≤ 10μM |
Z81284-2-O | NCI-H647 (cluster #2 Of 2), Other | Other | 70 | 0.36 | Functional ≤ 10μM |
Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
---|---|---|---|---|---|
TOP2A_HUMAN | P11388 | DNA Topoisomerase II Alpha, Human | 1000 | 0.30 | Binding ≤ 1μM |
TOP2B_HUMAN | Q02880 | DNA Topoisomerase II Beta, Human | 1000 | 0.30 | Binding ≤ 1μM |
KCNH2_HUMAN | Q12809 | HERG, Human | 208.929613 | 0.33 | Binding ≤ 1μM |
TOP2A_HUMAN | P11388 | DNA Topoisomerase II Alpha, Human | 1000 | 0.30 | Binding ≤ 10μM |
TOP2B_HUMAN | Q02880 | DNA Topoisomerase II Beta, Human | 1000 | 0.30 | Binding ≤ 10μM |
KCNH2_HUMAN | Q12809 | HERG, Human | 208.929613 | 0.33 | Binding ≤ 10μM |
S22A1_HUMAN | O15245 | Solute Carrier Family 22 Member 1, Human | 5000 | 0.27 | Binding ≤ 10μM |
Z80612 | Z80612 | 2008 (Ovarian Carcinoma Cells) | 4310 | 0.27 | Functional ≤ 10μM |
Z81034 | Z81034 | A2780 (Ovarian Carcinoma Cells) | 100 | 0.35 | Functional ≤ 10μM |
Z103205 | Z103205 | A431 | 170 | 0.34 | Functional ≤ 10μM |
Z80682 | Z80682 | A549 (Lung Carcinoma Cells) | 30 | 0.38 | Functional ≤ 10μM |
Z80064 | Z80064 | CCRF-CEM (T-cell Leukemia) | 130 | 0.34 | Functional ≤ 10μM |
Z80084 | Z80084 | CEM-VLB (Vinblastine-resistant T-cell Leukemia Cells) | 520 | 0.31 | Functional ≤ 10μM |
Z80085 | Z80085 | CEM-VM1 (Etoposide-resistant T-cell Leukemia Cells) | 1910 | 0.29 | Functional ≤ 10μM |
Z80089 | Z80089 | CHO-AA8 | 0.6 | 0.46 | Functional ≤ 10μM |
Z80115 | Z80115 | DC3F | 4 | 0.42 | Functional ≤ 10μM |
Z80117 | Z80117 | DC3F/AD-II | 47 | 0.37 | Functional ≤ 10μM |
TOP1_HUMAN | P11387 | DNA Topoisomerase I, Human | 37 | 0.37 | Functional ≤ 10μM |
TOP1_MOUSE | Q04750 | DNA Topoisomerase I, Mouse | 12 | 0.40 | Functional ≤ 10μM |
TOP2A_HUMAN | P11388 | DNA Topoisomerase II Alpha, Human | 37 | 0.37 | Functional ≤ 10μM |
TOP2A_MOUSE | Q01320 | DNA Topoisomerase II Alpha, Mouse | 12 | 0.40 | Functional ≤ 10μM |
TOP2B_MOUSE | Q64511 | DNA Topoisomerase II Beta, Mouse | 12 | 0.40 | Functional ≤ 10μM |
TOP2B_HUMAN | Q02880 | DNA Topoisomerase II Beta, Human | 37 | 0.37 | Functional ≤ 10μM |
Z80846 | Z80846 | F460pv8/eto Cell Line | 40 | 0.37 | Functional ≤ 10μM |
Z80928 | Z80928 | HCT-116 (Colon Carcinoma Cells) | 6300 | 0.26 | Functional ≤ 10μM |
Z80152 | Z80152 | HCT-8 (Ileocecal Adenocarcinoma) | 120 | 0.35 | Functional ≤ 10μM |
Z81247 | Z81247 | HeLa (Cervical Adenocarcinoma Cells) | 12 | 0.40 | Functional ≤ 10μM |
Z80156 | Z80156 | HL-60 (Promyeloblast Leukemia Cells) | 1150 | 0.30 | Functional ≤ 10μM |
Z80166 | Z80166 | HT-29 (Colon Adenocarcinoma Cells) | 559 | 0.31 | Functional ≤ 10μM |
Z81244 | Z81244 | J774 (Macrophage Cells) | 900.6 | 0.30 | Functional ≤ 10μM |
Z80819 | Z80819 | J774.2 | 1353.9 | 0.29 | Functional ≤ 10μM |
Z81072 | Z81072 | Jurkat (Acute Leukemic T-cells) | 1000 | 0.30 | Functional ≤ 10μM |
Z80186 | Z80186 | K562 (Erythroleukemia Cells) | 23 | 0.38 | Functional ≤ 10μM |
Z80193 | Z80193 | L1210 (Lymphocytic Leukemia Cells) | 33 | 0.37 | Functional ≤ 10μM |
Z50460 | Z50460 | Leishmania Major | 1500 | 0.29 | Functional ≤ 10μM |
Z81160 | Z81160 | Lewis Lung Carcinoma Cell Line | 12 | 0.40 | Functional ≤ 10μM |
Z81164 | Z81164 | LL Cell Line | 12 | 0.40 | Functional ≤ 10μM |
Z81167 | Z81167 | LLTC Cell Line | 12 | 0.40 | Functional ≤ 10μM |
Z80224 | Z80224 | MCF7 (Breast Carcinoma Cells) | 5130 | 0.26 | Functional ≤ 10μM |
Z80227 | Z80227 | MCF7-ADR (Breast Carcinoma Cells) | 1165 | 0.30 | Functional ≤ 10μM |
Z81252 | Z81252 | MDA-MB-231 (Breast Adenocarcinoma Cells) | 140 | 0.34 | Functional ≤ 10μM |
Z80244 | Z80244 | MDA-MB-468 (Breast Adenocarcinoma) | 490 | 0.32 | Functional ≤ 10μM |
Z81280 | Z81280 | NCI-H226 (Non-small Cell Lung Carcinoma Cells) | 1010 | 0.30 | Functional ≤ 10μM |
Z80889 | Z80889 | NCI-H322M (Non-small Cell Lung Carcinoma Cells) | 210 | 0.33 | Functional ≤ 10μM |
Z80322 | Z80322 | NCI-H358 (Lung Carcinama Cells) | 150 | 0.34 | Functional ≤ 10μM |
Z81024 | Z81024 | NCI-H460 (Non-small Cell Lung Carcinoma) | 200 | 0.33 | Functional ≤ 10μM |
Z81284 | Z81284 | NCI-H647 | 70 | 0.36 | Functional ≤ 10μM |
Z80362 | Z80362 | P388 (Lymphoma Cells) | 12 | 0.40 | Functional ≤ 10μM |
Z50425 | Z50425 | Plasmodium Falciparum | 1000 | 0.30 | Functional ≤ 10μM |
Z80475 | Z80475 | SK-BR-3 (Breast Adenocarcinoma) | 60 | 0.36 | Functional ≤ 10μM |
Z80712 | Z80712 | T47D (Breast Carcinoma Cells) | 220 | 0.33 | Functional ≤ 10μM |
Z80601 | Z80601 | XRS6 | 240 | 0.33 | Functional ≤ 10μM |
Z80608 | Z80608 | ZR-75-1 (Breast Carcinoma Cells) | 180 | 0.34 | Functional ≤ 10μM |
ADO_RAT | Q9Z0U5 | Aldehyde Oxidase, Rat | 3000 | 0.28 | ADME/T ≤ 10μM |
ADO_HUMAN | Q06278 | Aldehyde Oxidase, Human | 3200 | 0.27 | ADME/T ≤ 10μM |
ADO_RABIT | P80456 | Aldehyde Oxidase, Rabit | 60 | 0.36 | ADME/T ≤ 10μM |
CP2D6_HUMAN | P10635 | Cytochrome P450 2D6, Human | 7500 | 0.26 | ADME/T ≤ 10μM |
Description | Species |
---|---|
Abacavir transmembrane transport | |
CYP2E1 reactions | |
Fatty acids | |
G0 and Early G1 | |
Miscellaneous substrates | |
Na+/Cl- dependent neurotransmitter transporters | |
Neurotransmitter Clearance In The Synaptic Cleft | |
Norepinephrine Neurotransmitter Release Cycle | |
Organic cation transport | |
Vitamins B6 activation to pyridoxal phosphate | |
Voltage gated Potassium channels | |
Xenobiotics |